The Michigan Technology and Research Institute and Wayne State University have partnered to commercialize three small molecule compounds developed by WSU researchers with the potential to treat an array of neurological conditions, the university said this week.

As part of their deal, MITRI and WSU have inked a letter of intent to form a company to ready for clinical trials the most advanced of the compounds, a small molecule triple-uptake inhibitor for treating depression, at which point they hope to attract a pharma partner for further development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.